Vaxart (VXRT) Declines 36% Following Data from Phase 1 Clinical Trial Evaluating Oral COVID-19 Tablet Vaccine Candidate

February 3, 2021 8:44 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Vaxart (NASDAQ: VXRT) Declines 36% Following Data from Phase 1 Clinical Trial Evaluating Oral COVID-19 Tablet Vaccine Candidate



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot FDA News, Trader Talk